Predicting individual survival after potentially curative esophagectomy for adenocarcinoma of the esophagus or gastroesophageal junction

Annals of Surgery

Volumn 248, Issue 6, 2008, Pages 1006-1012

  Lagarde, Sjoerd M ^a,b   Reitsma, J B ^c   Ten Kate, F J W ^a   Busch, O R C ^a   Obertop, H ^a   Zwinderman, A H ^c   Moons, J ^d   Van Lanschot, J J B ^a   Lerut, T ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c Biostatistics and Bioinformatics ^*  (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BELGIUM; CALIBRATION; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RELIABILITY; VALIDATION STUDY; VALIDITY; ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; ESOPHAGUS TUMOR; LYMPH NODE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SURVIVAL; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; SURVIVAL ANALYSIS;

EID: 58149386917     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318190a0a2     Document Type: Article

References (36)

1. Botterweck AA, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 2000;29:645-654.
2. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-146.
3. van Blankenstein M, Looman CW, Hop WC, et al. The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus: Barrett's esophagus makes a difference. Am J Gastroenterol. 2005;100: 766 -774.
4. Siewert JR, Feith M, Werner M, et al. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/ topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232:353-361.
5. Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg. 1999;230:392-400.
6. Mariette C, Balon JM, Piessen G, et al. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 2003;97:1616-1623.
7. Lerut T, Coosemans W, De LP, et al. Reflections on three field lymph- adenectomy in carcinoma of the esophagus and gastroesophageal junction. Hepatogastroenterology. 1999;46:717-725.
8. Hulscher JB, van Sandick JW, Tijssen JG, et al. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg. 2000;191:143-148.
9. de Manzoni G, Pedrazzani C, Pasini F, et al. Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction. Eur J Surg Oncol. 2003;29:506-510.
10. American Joint Committee on Cancer. AJCC Cancer Staging Handbook. Philadelphia, PA: Lippincott-Raven; 2002.
11. TNM: classification of malignant tumours. New-York, NY: Wiley-Liss; 2002.
12. Steup WH, De Leyn P, Deneffe G, et al. Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg. 1996;111:85-94.
13. Rice TW, Blackstone EH, Rybicki LA, et al. Refining esophageal cancer staging. J Thorac Cardiovasc Surg. 2003;125:1103-1113.
14. Lerut T, Coosemans W, Decker G, et al. Extended surgery for cancer of the esophagus and gastroesophageal junction. J Surg Res. 2004; 117:58-63.
15. Korst RJ, Rusch VW, Venkatraman E, et al. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg. 1998;115:660-669.
16. Ellis FH Jr, Heatley GJ, Balogh K. Proposal for improved staging criteria for carcinoma of the esophagus and cardia. Eur JCardiothorac Surg. 1997;12:361-364.
17. Dickson GH, Singh KK, Escofet X, et al. Validation of a modified GTNM classification in peri-junctional oesophago-gastric carcinoma and its use as a prognostic indicator. Eur J Surg Oncol. 2001;27:641-644.
18. de Manzoni G, Pedrazzani C, Verlato G, et al. Comparison of old and new TNM systems for nodal staging in adenocarcinoma of the gastrooesophageal junction. Br J Surg. 2004;91:296 -303.
19. Lagarde SM, Reitsma JB, de Castro SM, et al. Prognostic nomogram for patients undergoing oesophagectomy for adenocarcinoma of the oesophagus or gastro-oesophageal junction. Br JSurg. 2007.
20. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330-4337.
21. Kleinberg L, Knisely JP, Heitmiller R, et al. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2003;56:328-334.
22. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. JClin Oncol. 2001;19:305-313.
23. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med. 1999;130:515-524.
24. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 2000;19:453-473.
25. Vergouwe Y, Steyerberg EW, Eijkemans MJ, et al. Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol. 2005;58:475-483.
26. Eloubeidi MA, Desmond R, Arguedas MR, et al. Prognostic factors for the survival of patients with esophageal carcinoma in the US: the importance of tumor length and lymph node status. Cancer. 2002;95: 1434-1443.
27. Clark GW, Peters JH, Ireland AP, et al. Nodal metastasis and sites of recurrence after en bloc esophagectomy for adenocarcinoma. Ann Thorac Surg. 1994;58:646-653; discussion 653-654.
28. Holscher AH, Bollschweiler E, Bumm R, et al. Prognostic factors of resected adenocarcinoma ofthe esophagus. Surgery. 1995;118:845-855.
29. Lagarde SM, ten Kate FJ, Reitsma JB. Prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. J Clin Oncol. 2006;24:4347-4355.
30. Fumagalli U. Panel of experts: resective surgery for cancer of the thoracic esophagus. Dis Esophagus. 1996;9:30-38.
31. Wind J, Lagarde SM, ten Kate FJ, et al. A systematic review on the significance of extracapsular lymph node involvement in gastrointestinal malignancies. Eur J Surg Oncol. 2007;33:401-408.
32. Lagarde SM, ten Kate FJ, de Boer DJ, et al. Extracapsular lymph node involvement in node-positive patients with adenocarcinoma of the distal esophagus or gastroesophageal junction. Am J Surg Pathol. 2006;30: 171-176.
33. Lerut T, Coosemans W, Decker G, et al. Extracapsular lymph node involvement is a negative prognostic factor in T3 adenocarcinoma of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg. 2003;126:1121-1128.
34. Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am JSurg. 2002;183: 274-279.
35. Fiorica F, Di BD, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004; 53:925-930.
36. Brennan MF, Kattan MW, Klimstra D, et al. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004;240:293-298.